EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

about

Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.

P2860

Q55710454-24983729-A6C9-466F-9F72-EB50CDB556A7

P2860

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

Item

http://www.wikidata.org/entity/Q47375034

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

@en

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

@nl

type

Item

label

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

@en

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

@nl

prefLabel

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

@en

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

@nl

P1476

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

@en

P2093

Behrouz Zandieh-Doulabi

http://www.w3.org/2001/XMLSchema#string

Fateme Haghiralsadat

http://www.w3.org/2001/XMLSchema#string

Jantine Posthuma De Boer

http://www.w3.org/2001/XMLSchema#string

Kamran Nazmi

http://www.w3.org/2001/XMLSchema#string

Marco N Helder

http://www.w3.org/2001/XMLSchema#string

Samira Naderinezhad

http://www.w3.org/2001/XMLSchema#string

Tymour Forouzanfar

http://www.w3.org/2001/XMLSchema#string

P2860

cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases

Targeting multidrug resistance in cancer

Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.

Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.

EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats.

Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery.

Osteosarcoma treatment: state of the art.

Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation.

Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.

P304

2891-2900

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11095-017-2272-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ghassem Amoabediny

P577

2017-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29110283

http://www.w3.org/2001/XMLSchema#string

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

about

P2860

P2860

EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698